Skip links

Oxlumo® (lumasiran)

Full Name Oxlumo® (lumasiran)
Drug Oxlumo
Manufacturer Alnylam Pharmaceuticals
Route of Administration Subcutaneous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients
Disease Primary Hyperoxaluria Type 1 (PH1)
Therapeutic Area Nephrology
Enrollment Form Link Oxlumo Enrollment Form
Phone Number 800-460-5217
Fax Number 877-276-8563
Product Website